期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1876, 期 2, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2021.188590
关键词
Triple-negative breast cancer; CDK4/6 inhibitor; Off-label indication
资金
- Key International Cooperation of the National Natural Science Foundation of China [81920108029]
The formation of cyclinD-CDK4/6 complex is essential for the cell cycle transition from G1 phase to S phase. CDK4/6 inhibitors can block cell cycle progression and proliferation, showing promising effects in containing the aggressiveness of breast cancers, particularly in triple-negative breast cancer.
The formation of cyclinD-CDK4/6 complex plays vital roles in the cell cycle transition from G1 phase to S phase which is characterized by vigorous transcription and synthesis. Through cyclinD-CDK4/6-Rb axis, CDK4/6 inhibitors arrest the cell cycle in the G1 phase and block the proliferation of aggressive cells, exhibiting promising effects in containing the aggressiveness of breast cancers. To date, there are three CDK4/6 inhibitors approved by the U.S. Food and Drug Administration in treating advanced hormone receptor-positive breast cancer, including palbociclib, abemaciclib, and ribociclib. In fact, several preclinical experiments and clinical trials presented therapeutic effects of CDK4/6 inhibitor-based treatment in triple-negative breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据